FMP
Kymera Therapeutics, Inc.
KYMR
NASDAQ
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
34.37 USD
0.92 (2.68%)
Historical Prices
From:
To:
About
ceo
Dr. Nello Mainolfi M.D., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.kymeratx.comexchange
NASDAQ
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fi...
CIK
0001815442
ISIN
US5015751044
CUSIP
501575104
Address
200 Arsenal Yards Boulevard
Phone
857 285 5300
Country
US
Employee
188
IPO Date
Aug 21, 2020
Financial Statement
Earnings
KYMR Financial Summary
CIK
0001815442
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
501575104
ISIN
US5015751044
Country
US
Price
34.37
Beta
2.23
Volume Avg.
580.1k
Market Cap
2.23B
Shares
-
52-Week
29.07-53.27
DCF
-11.75
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-11.53
P/B
-
Website
https://www.kymeratx.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest KYMR News
Zacks Investment Research
Aug 20, 2024
Kymera (KYMR) to Raise $225 Million Through Offering of Shar...
Kymera (KYMR) is in the process of selling approximately 2 million shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares in the offering.
Seeking Alpha
Aug 10, 2024
Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Trans...
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants Justine Koenigsberg - Vice President, Investor Relations Nello Mainolfi - Founder, President & CEO Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Eric Joseph - J.P. Morgan Jeff Jones - Oppenheimer Kelly Shi - Jefferies Vikram Purohit - Morgan Stanley Brad Canino - Stifel Nicolaus Marc Frahm - TD Cowen Kalpit Patel - B.
Zacks Investment Research
Aug 8, 2024
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Fo...
Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
Zacks Investment Research
Aug 7, 2024
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Reven...
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.67 per share a year ago.
GlobeNewsWire
Jul 31, 2024
Kymera Therapeutics to Report Second Quarter 2024 Financial ...
Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report second quarter 2024 financial results on August 7, 2024, and will host a conference call at 8:30 a.m. ET.
Seeking Alpha
Jul 16, 2024
Kymera Therapeutics: Solid Progress And No Change To My 'Buy...
Kymera Therapeutics is a protein degradation specialist drug developer with promising Phase 1 and 2 stage protein degraders targeting various diseases. A partnership with Sanofi includes potential milestone payments of up to $1.48 billion for IRAK4 program, showing strong financial backing and support. I am expecting to see Positive data from Phase 2 studies of KT-474 expected in 1H25, with potential for significant share price increase and future M&A opportunities.
Zacks Investment Research
Jul 10, 2024
Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indicati...
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Motley Fool
Jul 9, 2024
Why Kymera Therapeutics Stock Is Soaring Today
Sanofi plans to expand phase 2 clinical studies evaluating Kymera's KT-474. This move could accelerate pivotal testing for the potential skin treatment.
